Policy Update: TrumpRx Price Comparisons

On Feb. 5, President Donald Trump unveiled the long-awaited rollout of TrumpRx.gov, the administration’s new direct-to-consumer pharmaceutical pricing website. The announcement marks one of several steps taken by the Trump administration to reduce the cost of pharmaceuticals by delivering Most-Favored-Nation (MFN) drug pricing arrangements to patients, including the development of voluntary MFN pricing arrangements with 17 major manufacturers and international reference pricing models through the CMS Innovation Center. While the TrumpRx platform promises to provide cash-paying American patients with “direct access to dramatically lower prices on dozens of common, high-cost brand-name prescription drugs,” the savings presented may not differ significantly from that already offered through existing discount programs or traditional prescription drug insurance coverage.

Full Brief